Monday, November 12, 2012

Buck Institute, partner spawn startup

Stelios Tzannis and Brian Kennedy.
The Buck Institute for Research on Aging and a for-profit partner are spinning out their research into a new company.
Delos Pharmaceuticals Inc., which is seeking about $6 million in a Series A fundraising round, is focusing on developing drugs that could target neurodegnerative diseases, cancer, cardiovascular disease and metabolic diseases such as lupus. The company, with CEO Stelios Tzannis as its sole employee, is housed at the Novato-based Buck Institute.
It is the first company spun off by the 13-year-old institute, said Buck President and CEO Brian Kennedy, but there will be more.

No comments:

Post a Comment